BioSpace News Archive

GW Pharmaceuticals plc announces the submission of a Type II Variation Application to the European Medicines Agency seeking approval of EPIDYOLEX®, oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex, a rare genetic condition and a leading cause of genetic epilepsy.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today provided a statement on a safety alert from the U.S. Food and Drug Administration (FDA) regarding bloodstream infections with multi-drug resistant organisms (MDROs) transmitted through fecal microbiota transplantation (FMT).

Can-Fite to Support Research Directed by Kamel Khalili, Ph.D. on Piclidenoson against Coronaviruses.

Luminex Corporation (NASDAQ: LMNX) announced today that four independent clinical laboratories have validated laboratory developed tests (LDTs) for automated, rapid detection of the SARS-CoV-2 virus using the sample-to-answer ARIES® System.

Science 37, the industry leader in decentralized clinical trials, today published a report examining key considerations for patient safety and business continuity in the clinical trial industry in light of the current COVID-19 pandemic.

Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the fourth quarter and fiscal year ended December 31, 2019 and provided a business update.

Veravas, Inc., an emerging diagnostic company focusing on sample preparation products and new diagnostic tests and MIP Diagnostics Ltd., the Molecularly Imprinted Polymers (MIPs) specialist based in Sharnbrook, United Kingdom, announced today that they have entered into a mutually beneficial agreement for the development, license, and supply of a novel MIP specific for Veravas’ proprietary sample preparation technology.

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2019, as well as recent business highlights.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019, and provided a corporate update.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the fourth quarter and full year 2019 and provided a business update.